Joyzyme Group Limited (HKG:8622)

Market Cap	185.57M +45.4%
Revenue (ttm)	28.24M +2.7%
Net Income	-5.20M
EPS	-0.01
Shares Out	515.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,000
Average Volume	333,600
Open	0.3600
Previous Close	0.3600
Day's Range	0.3500 - 0.3600
52-Week Range	0.2750 - 0.7500
Beta	0.69
RSI	38.99
Earnings Date	Nov 14, 2025

About Joyzyme Group

Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. The company was formerly known as ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8622

Financial Performance

In 2024, Joyzyme Group's revenue was 25.36 million, an increase of 2.96% compared to the previous year's 24.63 million. Losses were -4.16 million, -28.09% less than in 2023.

Financial numbers in CNY